Cannabis

# Research Output: Cannabis

## Botanical Identity

**Accepted binomial:** *Cannabis sativa* L.
**Authority & publication:** Linnaeus, *Species Plantarum* (1753) [Ref 26]
**Family:** Cannabaceae (hemp family)
**Synonyms:** *Cannabis indica* Lam., *Cannabis ruderalis* Janisch., plus 33 additional intraspecific variants (var. *afghnica*, var. *chinensis*, etc.) — 36 synonyms total recognised by POWO [Ref 26]
**POWO accession:** LSID ipni.org:names:306087-2 [Ref 26]

**Taxonomy notes:** The genus *Cannabis* is monotypic (one accepted species: *C. sativa*). Taxonomic debate over whether *indica* and *ruderalis* deserve species or subspecies recognition is ongoing. McPartland (2018) recognises two subspecies: *C. sativa* subsp. *sativa* (fibre/hemp chemotypes; CBD > THC) and *C. sativa* subsp. *indica* (drug chemotypes; THC > CBD) [Ref 24]. Vernacular "sativa" vs "indica" strain names as used in cannabis retail settings do not align with formal botanical taxonomy and have been described as "almost meaningless" due to ubiquitous interbreeding [Ref 24]. **Seed data discrepancy:** The brief lists no botanical family or genus/species data — this section fills those gaps entirely from primary sources.

**Native range:** Central Asia to Xinjiang (northwestern China) and Pakistan (POWO) [Ref 26]. Genomic analysis of 110 accessions confirms East Asia as the centre of domestication [Ref 25].

**Cultivation status:** Both wild (feral landraces) and extensively cultivated globally. Now introduced across six continents in temperate and subtropical zones [Ref 26]. Annual herb; grows primarily in temperate biome [Ref 26]. Major cultivated regions include: Afghanistan (drug cultivars), China (hemp/fibre), Netherlands, Canada, United States (medical and adult-use markets), Morocco (hashish), India (bhang, charas).

**Morphological notes:** Dioecious (male and female flowers on separate plants), occasionally monoecious [Ref 3]. Flowering female plants (inflorescences) contain the highest concentration of cannabinoids, concentrated in glandular trichomes on bracts [Ref 22]. No documented misidentification risk with toxic look-alikes under normal conditions, though hemp (*C. sativa* subsp. *sativa*, THC < 0.3%) is frequently confused for high-THC drug-type cannabis in visual inspection.

**Chemotypes:** Three chemotypes are formally recognised [Ref 24]:
- **Type I (Drug-type):** THC-dominant (THC:CBD ratio >>1); subsp. *indica* sensu McPartland
- **Type II (Intermediate):** Roughly balanced THC:CBD
- **Type III (Fibre/hemp-type):** CBD-dominant or THC < 0.3%; subsp. *sativa* sensu McPartland

---

## Alkaloid / Cannabinoid Profile

**Overview:** Cannabis synthesises >100 phytocannabinoids, plus hundreds of terpenes and flavonoids [Ref 5, Ref 22]. Total identified compounds: ~400+ [Ref 5]. Cannabinoids are concentrated in glandular trichomes of the female flower.

### Major Cannabinoids (PubChem-verified)

| Compound | PubChem CID | Molecular Formula | MW |
|---|---|---|---|
| Δ9-Tetrahydrocannabinol (THC) | 16078 | C₂₁H₃₀O₂ | 314.5 g/mol |
| Cannabidiol (CBD) | 644019 | C₂₁H₃₀O₂ | 314.5 g/mol |
| Cannabigerol (CBG) | 5315659 | C₂₁H₃₂O₂ | 316.5 g/mol |
| Cannabichromene (CBC) | 30219 | C₂₁H₃₀O₂ | 314.5 g/mol |
| Tetrahydrocannabinolic acid (THCA) | 3082459 | C₂₂H₃₀O₄ | 358.5 g/mol |

*InChIKeys verified via PubChem database.*

**THC (Δ9-THC):** Primary psychoactive constituent. InChIKey: CYQFCXCEBYINGO-IAGOWNOFSA-N. CB1 and CB2 receptor partial agonist [Ref 5, Ref 21]. Responsible for euphoria, relaxation, altered perception, and associated adverse effects including anxiety, psychosis risk [Ref 5]. Exists predominantly as THCA (acid precursor) in the raw plant; decarboxylated to active THC by heat [Ref 34].

**CBD (Cannabidiol):** Second most abundant cannabinoid in drug-type varieties; dominant in hemp. InChIKey: QHMBSVQNZZTUGM-ZWKOTPCHSA-N. Non-intoxicating. Acts as non-competitive negative allosteric modulator of CB1, inverse agonist at CB2, inhibits anandamide reuptake, activates 5-HT1A serotonergic receptors and TRPV1 vanilloid receptors [Ref 5, Ref 6]. CBD does not produce the typical psychoactive effects of THC and has anxiolytic and antipsychotic effects [Ref 5]. CBD inhibits CYP-mediated metabolism of clobazam (an antiepileptic) [Ref 40]. At CBD:THC ratios up to 3:1, CBD does not significantly attenuate the acute adverse effects of 10mg THC in a controlled RCT [Ref 12].

**CBG (Cannabigerol):** Biosynthetic precursor to THC, CBD, and CBC; typically <1% in mature drug-type plants. Activates TRPV1, TRPV2, and acts as TRPM8 antagonist [Ref 45]. Some analgesic and antibacterial activity in preclinical models.

**CBC (Cannabichromene):** Non-intoxicating; TRPA1 agonist [Ref 45]. Anti-inflammatory preclinical data.

**THCA:** Non-psychoactive acid form; decarboxylates to THC upon heating. GC-MS without derivatization achieves only ~50-60% decarboxylation efficiency, leading to underestimation of total THC in cannabis oil analyses [Ref 34]. LC-MS preferred for accurate total cannabinoid quantification.

**CBN (Cannabinol):** Degradation product of THC via oxidation; found in aged cannabis. Mild sedative properties; TRPA1 agonist [Ref 45].

**THCV (Tetrahydrocannabivarin):** CB1 antagonist at low doses; possible CB1 agonist at high doses; CB2 partial agonist [Ref 21]. Appetite-suppressing properties in preclinical models.

**Terpenes:** β-myrcene (relaxing, sedating), D-limonene (anxiolytic in controlled study [Ref 18]), β-caryophyllene (CB2 partial agonist), α-humulene, linalool, pinene, terpinolene — each with their own pharmacological activities. Cannabis terpenes act as partial agonists at CB1R and CB2R with EC50 values at or below those of THC in some preparations [Ref 41 PubMed 41173057 - selective activation by terpenes]. D-limonene co-administration selectively mitigated the acute anxiogenic effects of vaporised THC in a controlled crossover study [Ref 18].

**Concentration variability:**
- Commercial dried flower: THC ranges from <1% (hemp) to >30% (high-potency drug-type) [Ref 17]. Mean THC in NY State medical marijuana products found to be consistent and stable (CV <3% within lot) [Ref 17].
- Modern high-potency concentrates (wax, dabs, shatter): THC content 50–90%+ [Ref 29].
- The "entourage effect" — the hypothesis that multiple cannabis constituents act synergistically — has empirical support from terpene studies [Ref 18] but has not been consistently confirmed in clinical trials [Ref 12].

**Decarboxylation (preparation-critical):** Heating raw cannabis (smoking, vaporizing, cooking) converts THCA to active THC. Incomplete decarboxylation occurs with some analytical methods [Ref 34]. Oral administration of raw cannabis juice (unheated) delivers THCA, not THC, and produces no psychoactive effects.

---

## History & Ethnobotany

**Archaeological and pre-modern use:**
Cannabis is among the oldest cultivated plants. Archaeological evidence confirms domestication in East Asia during early Neolithic times [Ref 25]. Whole-genome resequencing of 110 accessions demonstrates that all current hemp and drug cultivars diverged from an ancestral gene pool currently represented by feral plants and landraces in China [Ref 25]. Archaeobotanical evidence of medicinal cannabis use in secular (non-ritual) contexts has been recovered from southern China [Ref 2]. Cannabis was used in medicine before the Christian era across Asia, principally in India for ritual, fibre, food, and medicinal purposes [Ref 39].

**Traditional use:**
- India: Ritual use of *bhang* (oral preparation), *charas* (hand-rubbed resin), and *ganja* (dried flower). Documented in Vedic texts.
- China: Listed in *Shennong Bencao Jing* (~100 CE) for over 100 conditions.
- Middle East, Central Asia: Hashish (compressed resin) widely described by 13th century CE Arab scholars.

*These are historical and cultural facts. Traditional use accounts are not evidence of safety or efficacy. Flag: Traditional-use accounts for specific therapeutic claims lack clinical confirmation — flag for human review.*

**Western scientific history:**
- 1839: William B. O'Shaughnessy introduced cannabis medicine to European medicine after observing its use in India.
- Mid-to-late 19th century: Cannabis extracts and tinctures became available in Western pharmacopeias; use peaked, then declined due to inconsistent potency [Ref 39].
- ~1965: Raphael Mechoulam and colleagues at the Hebrew University of Jerusalem identified and isolated Δ9-THC and determined its chemical structure, igniting modern cannabinoid research [Ref 39].
- 1988: First cannabinoid receptor (CB1) identified by Allyn Howlett and William Devane.
- 1991: Herkenham et al. characterised and localised CB1 receptors in rat brain by quantitative autoradiography; dense binding in basal ganglia, cerebellar molecular layer, hippocampus [Ref 19].
- 1992: Anandamide (AEA, arachidonoylethanolamide) identified as the first endogenous cannabinoid ligand.
- 1993: CB2 receptor cloned.
- 1995: 2-Arachidonoylglycerol (2-AG) identified as endogenous CB1/CB2 agonist.
- 2005: Sativex (nabiximols, CBD+THC oromucosal spray) approved in Canada for central neuropathic pain in MS.
- 2018: FDA approved Epidiolex (purified CBD) for Dravet syndrome and Lennox-Gastaut syndrome.

**Regulatory timeline:**
- 1937: US Marihuana Tax Act effectively prohibited cannabis in the United States.
- 1961: Cannabis placed in Schedule I and Schedule IV of the UN Single Convention on Narcotic Drugs [Ref 60].
- 1970: Cannabis placed in Schedule I of the US Controlled Substances Act (CSA) [Ref 49].
- 1996: California became first US state to legalise medical cannabis (Prop 215).
- 2012: Colorado and Washington became first US states to legalise recreational cannabis.
- 2018: Canada enacted the Cannabis Act; recreational use federally legalised October 17, 2018 [Ref 58].
- 2018: UK permitted medical cannabis prescriptions.
- December 2, 2020: UN Commission on Narcotic Drugs voted 27-25-1 to remove cannabis from Schedule IV of the 1961 Convention (retains Schedule I listing) [Ref 60].
- April 1, 2024: Germany enacted the Cannabis Act (CanG), legalising adult recreational use [Ref 59].
- 2024: US DOJ initiated rulemaking to reschedule cannabis to Schedule III of the CSA [Ref 49].
- 2026 (May): Acting US Attorney General reclassified state-approved medical cannabis to Schedule III [Ref 49].

---

## Neuroscience & Mechanism

**Primary receptor targets:**
- **CB1 receptor:** G-protein coupled receptor (Gi/o-coupled); dense expression in cortex, basal ganglia, hippocampus, cerebellum, amygdala [Ref 19]. THC acts as a partial agonist at CB1, producing reduced neuronal firing, decreased cyclic AMP, and modulation of neurotransmitter release [Ref 4, Ref 21]. CB1 activation mediates most of THC's psychoactive effects, including euphoria, reward, cognitive impairment, and anxiolytic/anxiogenic effects [Ref 4].
- **CB2 receptor:** Expressed primarily in immune cells and peripheral tissues; also present in CNS microglia and neurons [Ref 4]. THC is also a CB2 partial agonist. CB2 activation appears to modulate immune function, inflammation, and (paradoxically) aversion/dopamine signalling [Ref 4]. THCV acts as CB1 antagonist (low dose) / agonist (high dose) and CB2 partial agonist [Ref 21].
- **CBD's targets:** CBD acts as a negative allosteric modulator of CB1 (does not produce typical THC effects), inverse agonist at CB2, 5-HT1A partial agonist (anxiolytic), TRPV1 agonist/desensitiser, inhibitor of anandamide reuptake via AEA uptake transporter [Ref 5, Ref 6, Ref 45]. CBD weakly inhibits FAAH (anandamide hydrolase) at higher concentrations [Ref 45].
- **Other targets:** GPR55 (novel cannabinoid receptor); PPAR-γ; adenosine, opioid, serotonin receptor modulation [Ref 4, Ref 23]. Cannabis terpenes (including myrcene, limonene, β-caryophyllene) activate CB1R and CB2R as partial agonists [Ref 18].

**Endocannabinoid system (ECS):**
The ECS comprises CB1 and CB2 receptors, endogenous ligands (anandamide/AEA and 2-arachidonoylglycerol/2-AG), and biosynthetic/catabolic enzymes (FAAH for AEA, MAGL for 2-AG) [Ref 62]. Endocannabinoids act as retrograde synaptic messengers — released postsynaptically and acting on presynaptic CB1 receptors to inhibit neurotransmitter release [Ref 62]. THC hijacks this system through sustained CB1 activation (unlike phasic endocannabinoid signalling), producing prolonged downstream effects.

**Pharmacokinetics by route:**

*Inhalation (smoked or vaporised):*
- Onset: seconds to minutes (peak effects ~5–15 min) [Ref 14, Ref 40]
- Tmax: approximately 3–10 minutes [Ref 14, Ref 40]
- Bioavailability (smoked): approximately 10–35% (highly variable due to inhalation technique, puff volume, hold time) [Ref 40, Ref 7]
- Vaporisation: Comparable bioavailability to smoking, but without combustion byproducts; vaporiser provides immediate systemic absorption with highest Cmax of any preparation [Ref 48]
- Plasma THC half-life (single dose, infrequent users): ~2 hours; redistribution half-life much shorter [Ref 40]
- Plasma THC half-life (chronic heavy users): extended due to lipophilic tissue saturation; terminal half-life up to 5+ days [Ref 40]
- PK/PD equilibration half-life for CNS effects: ~40–80 minutes (significant lag between plasma THC peak and subjective peak) [Ref 14]

*Oral (edibles, capsules, tinctures):*
- Onset: 30 minutes to 2+ hours (highly variable) [Ref 7, Ref 40]
- Tmax: 1–3 hours (range 0.5–4 hours) [Ref 7]
- Bioavailability: 4–12% (low due to first-pass hepatic metabolism) [Ref 40]
- 11-OH-THC (active metabolite): produced during first-pass metabolism; crosses blood-brain barrier more efficiently than THC; may contribute significantly to the heightened psychoactive potency of oral preparations [Ref 7]
- Duration of effects: substantially longer than inhalation; typically 4–8 hours, occasionally longer [Ref 40]

*Sublingual (oromucosal, Sativex-type):*
- Faster onset than oral; variable absorption; Tmax intermediate between inhalation and oral [Ref 48]

**Metabolism:**
- Primary route: Hepatic CYP-mediated hydroxylation
- Key enzymes: CYP2C9 (primary for THC → 11-OH-THC), CYP3A4 (secondary) [Ref 11, Ref 40]
- 11-OH-THC is pharmacologically active; further metabolised to 11-nor-9-carboxy-THC (THCCOOH), the primary urinary metabolite (inactive) [Ref 42]
- CBD: metabolised by CYP2C19, CYP3A4; inhibits CYP2C9 and CYP3A4 [Ref 7, Ref 40]
- Both THC and CBD are highly lipophilic; extensively distributed to fat and brain tissue [Ref 7]
- CYP interactions: CBD (and Δ8-THC) inhibit CYP2C9 and CYP3A4 in dose-dependent, reversible manner — competitive inhibition of CYP2C9 (warfarin), noncompetitive inhibition of CYP3A4 (midazolam) [Ref 11]

**Blood-brain barrier:** THC crosses the BBB readily due to high lipophilicity. 11-OH-THC penetrates even more readily.

---

## Effects & Dose by Preparation

*Note: Cannabis articles use per-preparation dose framing. Dose values from controlled clinical studies are cited; unverified community dose data has been excluded.*

**General notes on dose-response:**
Effects are strongly dependent on: (1) THC percentage of the preparation; (2) route of administration; (3) CBD:THC ratio; (4) user tolerance; (5) set and setting; (6) individual pharmacogenomics. Effects at the same dose vary substantially between infrequent and regular users.

### Flower, Smoked or Vaporised

**Clinical dose context:** Ware et al. (2010) studied 25 mg of 9.4% THC cannabis (~2.35 mg THC delivered per inhalation session) inhaled via pipe three times daily; this produced significant pain reduction and improved sleep with acceptable tolerability [Ref 41]. Zuurman et al. (2008) administered 2, 4, 6, and 8 mg pure THC via Volcano vaporizer to healthy males; dose-dependent subjective effects (feeling high, external perception changes), body sway, and heart rate increases were observed [Ref 14].

**Typical dosing range (FLAG — not verified by a single primary clinical source; ranges synthesised from multiple studies and should be reviewed by human editor):**
- Threshold: ~1–2 mg THC inhaled
- Common/recreational: ~5–15 mg THC inhaled
- Heavy/experienced users: >25 mg THC inhaled

**Onset (inhalation):** Within seconds to 1–2 minutes; peak effects 5–15 minutes [Ref 14]
**Duration (inhalation):** 1–4 hours (typically 2–3 hours in controlled studies) [Ref 14]

**Subjective effects (from controlled human studies):** Euphoria ("feeling high"), altered auditory/visual perception, cognitive relaxation, creativity enhancement, memory impairment, increased appetite, dry mouth, tachycardia. At higher doses: anxiety, paranoia, thought disorganisation, disorientation [Ref 12, Ref 14, Ref 20].

### Oral (Edibles, Capsules, Oil)

**Clinical dose context:** The standard regulated dose in legal markets is 10 mg THC per serving (US state and Canadian regulations). Oral bioavailability is 4–12%; 11-OH-THC active metabolite produced; longer-lasting and sometimes more intense effects than equivalent smoked dose [Ref 7, Ref 40].

**Onset:** 30 minutes to 2 hours [Ref 7]
**Peak:** 2–4 hours [Ref 7]
**Duration:** 4–8 hours; possibly longer in naive users [Ref 40]

**Cardiovascular and respiratory effects minimal** compared to smoked route [Ref 54].

*FLAG: No single published controlled dose-finding study provides definitive threshold/common/heavy oral dose ranges for naive human subjects. The 10 mg/serving regulatory standard reflects policy consensus rather than a specific PK/PD threshold. Flag for human editor review.*

### Concentrated Extracts (Wax, Shatter, Oil, Dabs)

High-potency (50–90%+ THC). Dabbing (flash-vaporization) produces rapid, high-dose THC exposure. Case reports document emergent psychosis in individuals without prior psychiatric history following dab use [Ref 30]. National survey data confirms concentrates are becoming a common route for recreational users in the US [Ref 29].

*FLAG: No controlled clinical trial data on specific dose-response for cannabis concentrates in human subjects. Community dose data exists but is not cited here per protocol.*

### Oromucosal Spray (e.g., Sativex/nabiximols)

2.7 mg THC + 2.5 mg CBD per actuation. Standard clinical dosing in trials: up to 12 actuations per day. Route bypasses first-pass effect partially; PK intermediate between inhalation and oral [Ref 48].

**Effect modifiers:** Chemotype (Type I vs Type III has dramatically different subjective profiles), batch potency variability, user tolerance (regular users require substantially higher doses for equivalent effects), CBD:THC ratio (CBD does not protect against THC's acute adverse effects at common product ratios [Ref 12]), concurrent tobacco or alcohol use.

---

## Safety & Toxicity

### Acute Toxicity

No human fatality from cannabis alone has been documented in the published literature. Comparative risk assessment using the margin of exposure (MOE) approach demonstrates cannabis has an MOE > 10,000, compared with alcohol (MOE < 10 at individual level) and heroin (benchmark dose 2 mg/kg bodyweight) [Ref 51]. Animal LD50 values for THC are very high relative to any achievable human dose [Ref 51].

However, cannabis is not without acute adverse effects. Common adverse events in controlled trials include: dizziness, dry mouth, headache, dry eyes, nausea, somnolence, confusion, loss of balance, and tachycardia [Ref 20]. High-dose THC exposure can produce disorientation, confusion, and (in vulnerable individuals or with high-potency products) acute psychotic episodes [Ref 30, Ref 35].

### Cardiovascular

Tachycardia (acute heart rate increase) is the most consistent cardiovascular effect across all routes of administration, including smoking, vaporising, oral ingestion, and dabbing [Ref 54]. Potential for ventricular arrhythmias and myocardial infarction has been reported in the context of smoking, particularly with combined tobacco use [Ref 54]. Cardiac toxicity risk is increased with sympathomimetic drug combinations (additive hypertension and tachycardia) [Ref 40]. Cannabis is contraindicated in significant cardiovascular disease [Ref 40].

### Respiratory

- **Chronic bronchitis:** Strongly associated with regular cannabis smoking; characterised by increased mucus production, cough, and airway inflammation [Ref 55, Ref 56].
- **COPD:** No convincing causal link established; cannabis smoking does not consistently produce emphysema, but is associated with increased central airway resistance and lung hyperinflation [Ref 56].
- **Lung cancer:** Association remains inconclusive; some studies suggest increased risk with heavy long-term smoking, particularly in combination with tobacco [Ref 55, Ref 57].
- **Aspergillosis:** Cannabis smoke has been associated with invasive pulmonary aspergillosis in immunocompromised individuals [Ref 55].
- **Vaporisation vs smoking:** Vaporising avoids combustion byproducts; edibles are associated with minimal respiratory effects [Ref 54].
- **Nicotine/tobacco co-use:** Amplifies respiratory risks synergistically [Ref 57]. *(The brief flags nicotine as "caution" interaction — supported by respiratory and lung cancer risk amplification evidence [Ref 57]; no specific PK mechanism published.)*

### Cannabinoid Hyperemesis Syndrome (CHS)

Recurrent cyclic vomiting associated with chronic, heavy cannabis use; increasingly recognised in emergency departments as cannabis potency and use have increased [Ref 52, Ref 53]. Defined under ROME-IV criteria as a specific variant of cyclic vomiting syndrome [Ref 53]. Full remission requires sustained cannabis abstinence; cannabis relapses cause progressively stronger and longer CHS episodes (sensitisation) [Ref 53]. Management: hot baths/showers (diagnostic secondary criterion), haloperidol (up to 5 mg IM), topical capsaicin cream (0.075–0.1%) [Ref 53]. Treatment with aprepitant (NK1 receptor antagonist) shows promise in adolescent CHS refractory to standard antiemetics [Ref PubMed 40965394 — not in formal registry; note for human editor to review].

### Psychological Risks

**Psychosis and schizophrenia:** Epidemiological evidence consistently supports a dose-response relationship between cannabis use and psychosis risk; high-potency cannabis varieties confer the greatest risk [Ref 35, Ref 36]. Cannabis use is a component cause in multi-causal models where genetic vulnerability interacts with the precipitating substance [Ref 36]. Psychosis associated with cannabis withdrawal has also been documented in a systematic review [Ref 8].

**Acute anxiety and paranoia:** Common dose-dependent adverse effects, particularly in infrequent users and with high-THC preparations [Ref 12].

**Concentrates and psychosis:** Two case reports document emergent psychosis following use of high-potency wax/dabs in individuals with no prior psychiatric history [Ref 30].

**Cognitive effects:** Acute intoxication impairs short-term memory, attention, and executive function [Ref 20]. Chronic heavy use associated with reduced attentional/executive function, decreased mental flexibility, and increased perseveration [Ref PubMed 20512268]. Adolescent exposure associated with enduring cognitive effects, mesocorticolimbic dysregulation, and schizophrenia-like biomarkers [Ref 35].

### Dependence & Withdrawal

**Dependence liability:** Approximately 9% of cannabis users develop cannabis use disorder; risk is higher with earlier age of initiation and daily use [Ref PubMed 30193704 — not in formal registry; noted from text]. Cannabis dependence is the most common drug use disorder globally after opioid dependence, with 22.1 million cases estimated in 2016 [Ref 46].

**Withdrawal syndrome (cannabis withdrawal syndrome, CWS):** Occurs in approximately 50% of regular and dependent cannabis users after abrupt cessation or significant reduction [Ref 9]. DSM-5 diagnosable condition. Symptoms include: irritability, anxiety, insomnia, reduced appetite, restlessness, depressed mood. Onset: typically 1–3 days after cessation. Peak severity: 2–6 days. Duration: 2–3 weeks in most cases, though some symptoms may persist [Ref 9, Ref 10]. *FLAG: The brief's tolerance data ("Half-life: 1.5 weeks; Full reset: 2.5 weeks") could not be verified against a specific published primary source. This requires human review and citation verification.*

**Tolerance:** Develops with prolonged and repeated use, mediated by CB1 receptor downregulation and desensitisation [Ref 4, Ref 23]. Cross-tolerance within cannabinoids is established. Specific recovery timelines for CB1 receptor function vary across individuals and have not been definitively established in a single clean published human study.

**Treatment:** No approved pharmacotherapy for cannabis use disorder. FAAH inhibitor PF-04457845 showed promising signal in a Phase 2a RCT for cannabis withdrawal [Ref PubMed 30528676 — not in formal registry]. Psychosocial interventions are first-line [Ref PubMed 30530238].

### Herb–Drug Interactions

| Interaction Partner | Mechanism | Evidence Level |
|---|---|---|
| Opioids (morphine, oxycodone) | Pharmacodynamic synergism: additive analgesia; no significant PK interaction on opioid plasma levels observed | Clinical PK study [Ref 27] |
| Benzodiazepines (diazepam) | Pharmacodynamic: CNS depression additive; enhanced sedation expected | Mechanism-based inference; *FLAG: No specific clinical case report or quantitative PK study found for cannabis + diazepam interaction specifically* |
| GABAergic anesthetics (propofol, midazolam, isoflurane, sevoflurane) | Increased anesthetic requirements in cannabis users (clinical observation); molecular mechanism unclear | Clinical observation [Ref 28] |
| Sympathomimetics | Additive hypertension and tachycardia (cardiac toxicity risk) | Mechanism-based [Ref 40] |
| CYP substrates (warfarin, clobazam, midazolam) | THC/CBD inhibit CYP2C9 and CYP3A4; CBD specifically inhibits clobazam metabolism | In vitro + clinical case [Ref 11, Ref 40] |
| Tobacco / nicotine | Synergistic respiratory risks; amplified lung cancer risk | Epidemiological [Ref 57] |
| Alcohol | Both CNS depressants; combined use increases driving impairment additively; greater crash-related risk than either alone | Epidemiological/driving studies [Ref PubMed 27701009] |

*Note on interaction list in the brief: The brief lists many substances as "unknown" for interaction with cannabis. No published clinical pharmacokinetic data or case reports were found for the majority of these (e.g., LSD, psilocybin, 2C-x, NBOMe compounds, novel lysergamides). These remain appropriately classified as "unknown." Only the mechanistically plausible or clinically documented interactions are addressed above.*

### Contaminants & Adulterant Risk

Cannabis products are subject to multiple contamination risks in both regulated and unregulated markets:
- **Pesticides:** Numerous pesticide residues detected in commercial cannabis samples; state regulations in the US vary widely in allowable limits, analyte lists, and enforcement [Ref 15].
- **Heavy metals:** Cannabis can accumulate lead, cadmium, nickel, and other heavy metals through phytoremediation; hemp is particularly noted as a heavy metal accumulator [Ref 16].
- **Mycotoxins and mold:** Aspergillus species particularly concerning for immunocompromised consumers [Ref 55].
- **Label accuracy:** THC concentrations on commercial product labels may deviate substantially (±15% or more) from actual content; analytical discrepancies between different laboratory methods are documented [Ref 1, Ref 17].
- **Synthetic cannabinoids:** Not commonly documented as adulterants in regulated markets, but a risk in illicit markets.
- **Concentrate residual solvents:** Butane hash oil and other solvent-based extracts may contain residual solvents if not properly purged.

### Contraindications & Vulnerable Populations

- **Pregnancy:** Associated with lower birth weight, adverse neonatal outcomes, increased risk of preterm birth, small for gestational age, NICU admission [Ref 31, Ref 32, Ref 33]. THC crosses the placenta and interacts with fetal cannabinoid receptors [Ref 33]. Disrupts placental estrogen signalling [Ref PubMed 32647869]. Professional bodies universally discourage use during pregnancy [Ref 33].
- **Adolescents:** Critical developmental period; adolescent exposure associated with lasting cognitive and psychiatric effects [Ref 35].
- **Psychiatric disorders:** Contraindicated (or use with extreme caution) in personal or family history of psychotic disorders [Ref 40].
- **Cardiovascular disease:** Contraindicated due to cardiac effects [Ref 40].
- **Hepatic impairment:** THC and CBD extensively hepatically metabolised; impaired clearance expected [Ref 40].

---

## Harm Reduction

1. **Avoid smoking:** Combustion products are the primary driver of respiratory harm. Vaporisation significantly reduces exposure to harmful combustion byproducts; edibles avoid respiratory exposure entirely [Ref 54].
2. **Start low, go slow (especially oral routes):** Oral onset delay (30 min–2 hours) frequently leads to unintentional overconsumption [Ref 7, Ref 40].
3. **Avoid high-potency products and concentrates:** Dose-response relationship with adverse psychiatric effects; concentrates dramatically increase exposure risk [Ref 30, Ref 35].
4. **Avoid in adolescence:** Developing brain is particularly vulnerable [Ref 35].
5. **Avoid in pregnancy:** No safe threshold established [Ref 31, Ref 32, Ref 33].
6. **Avoid combining with CNS depressants:** Synergistic depression of CNS including respiratory function possible [Ref 28, Ref 40].
7. **Testing:** No reliable point-of-care testing for relative potency beyond commercial lab certificates; regulatory label accuracy may be ±15% [Ref 17, Ref 15].
8. **Cessation resources:** Cannabis use disorder treatment is predominantly psychosocial; no approved pharmacotherapy as of 2026 [Ref 9].
9. **CHS recognition:** Chronic heavy users with cyclic vomiting, episodic nausea, and compulsive hot showering should be evaluated for CHS; cessation is the only curative intervention [Ref 53].

---

## Legal Status

### United Nations (International Conventions)
- 1961 Single Convention on Narcotic Drugs: Cannabis and cannabis resin originally listed in Schedule I (high dependence potential) AND Schedule IV (most dangerous; no therapeutic value) [Ref 60].
- December 2, 2020: UN Commission on Narcotic Drugs voted 27-25-1 to remove cannabis from Schedule IV (based on WHO scientific assessment). Cannabis remains in Schedule I of the 1961 Convention [Ref 60].
- THC (Δ9-THC) is separately listed in the 1971 Convention on Psychotropic Substances.

### United States (Federal)
- Cannabis classified as Schedule I substance under the Controlled Substances Act (CSA) since 1970 [Ref 49].
- Schedule I criteria: high abuse potential; no accepted medical use; lack of accepted safety.
- 2024: US DOJ initiated rulemaking to reschedule cannabis to Schedule III [Ref 49].
- 2026 (April/May): Acting US Attorney General reclassified state-approved medical cannabis to Schedule III [Ref 49]. *FLAG: Rescheduling is in progress and may change — flag for human editor to verify current federal status.*

### United States (State Level)
- **California:** Recreational legal since Proposition 64 (November 2016, effective January 2018); medical since 1996 [Ref 61].
- **Colorado:** Recreational legal since Amendment 64 (November 2012); among first two states [Ref 61].
- **Washington:** Recreational legal since Initiative 502 (November 2012) [Ref 61].
- **Florida:** Medical only; recreational measure failed at November 2024 ballot [Ref 61].
- **Texas:** Illegal for recreational use; limited low-THC medical cannabis program (Compassionate Use) [Ref 61].
- As of 2024–2025: 24+ states have recreational cannabis; 47 states have medical cannabis programmes [Ref 15].

### Canada
- Cannabis Act (SC 2018, c. 16) came into force October 17, 2018 [Ref 58].
- First major industrialised country to legalise adult-use recreational cannabis nationally.
- Legal age: 18+ (provinces may increase to 19+; Ontario 19+) [Ref 58].
- Possession limit: 30 g dried cannabis (or equivalent) in public [Ref 58].
- Home cultivation: Up to 4 plants per residence from licensed seed/seedlings [Ref 58].

### United Kingdom
- Cannabis is a Class B controlled drug under the Misuse of Drugs Act 1971 [Ref 37].
- Recreational use illegal; possession carries up to 5 years imprisonment, supply up to 14 years.
- Medical cannabis prescriptions permitted since November 2018 (specialist prescriber only) [Ref 37].

### Germany
- Cannabis Act (Cannabisgesetz, CanG) came into force April 1, 2024 [Ref 59].
- Adults may possess personal amounts and home-cultivate; social clubs permitted.
- Germany is the largest country globally (by population) to have legalised adult recreational cannabis [Ref 59].

### Australia
- Medical cannabis: Regulated by Therapeutic Goods Administration (TGA) under Special Access Scheme (SAS) and Authorised Prescriber scheme; prescriptions permitted nationwide [Ref 50].
- Recreational cannabis: Federally illegal.
- **Australian Capital Territory (ACT):** Personal possession and home cultivation (up to 2 plants/person, 4/household) decriminalised since January 31, 2020; sale and supply remain illegal even in ACT [Ref 50].
- **Other territories and states:** Variable; some (NT, SA) have decriminalised small personal amounts with fines; most states (NSW, QLD, VIC, TAS, WA) maintain criminal penalties [Ref 50].

---

## Detection

**Primary analyte (urine):** 11-nor-9-carboxy-THC (THCCOOH), an inactive metabolite of THC [Ref 42, Ref 44]. THCCOOH is hydrophilic; it is excreted in urine as glucuronide conjugates.

**Standard immunoassay cutoff (workplace/legal):** 50 ng/mL THCCOOH in urine (US federal workplace standard) [Ref 44].

**Detection windows (general ranges; highly variable by use frequency and individual metabolism):**
- Infrequent/occasional use (~1x/week): Urine positive 3–7 days post-use
- Regular use (several times/week): 7–21 days
- Chronic daily use: 30+ days; in some cases months, due to lipophilic storage and slow redistribution [Ref 42]
- *FLAG: Specific detection windows vary substantially between individuals and have not been confirmed from a single published clinical study with validated cutoffs. Ranges above synthesised from multiple review sources [Ref 42, Ref 44].*

**Matrix-specific performance:**
- Urine: Most commonly tested; excellent specificity (100%), sensitivity varies (63–74% for moderate users); positive result confirms prior use, NOT current impairment [Ref 43, Ref 44]
- Oral fluid: Poor sensitivity (12% in one study) for urine-equivalent windows [Ref 43]
- Blood/plasma: Most reliable for acute impairment; plasma THCCOOH predicts depression symptoms (clinical utility) [Ref 43]; preferred for forensic/DUI assessments [Ref PubMed 27701009]
- Hair: Confirms chronic exposure history; not suitable for determining recent use [Ref 43]

**Preparations that trigger assays:** THC from any preparation (smoked, vaporised, oral, concentrate) produces THCCOOH. CBD-only preparations (hemp-derived, <0.3% THC) should not trigger THCCOOH tests, but labelling inaccuracies in commercial CBD products have led to unexpected positives. THCA from raw cannabis (juice) without heat may not convert to detectable THC. Synthetic cannabinoids are NOT detected by standard cannabinoid immunoassays.

---

## Clinical Trials

Active and recently completed trials at ClinicalTrials.gov:

1. **NCT04201197** (Completed, Phase 1): "Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs" — Johns Hopkins University. Directly characterises cannabinoid-CYP drug interactions.

2. **NCT05052541** (Recruiting, Phase 3): "Safety and Efficacy of Oral Cannabis in Chronic Spine Pain" — University of Colorado, Denver. Phase 3 trial of oral cannabis for back/neck pain.

3. **NCT04280289** (Completed, Early Phase 1): "CBD Cannabis Extract: Pharmacokinetic Studies" — University of Mississippi. Characterises CBD PK in epilepsy context.

4. **NCT01893424** (Completed, Phase 1): "Bioequivalence Assessment of Oral vs Oral Spray Administration of Cannabinoids (THC and CBD)" — Hadassah Medical Organization.

5. **NCT04883255** (Recruiting, Early Phase 1): "Cannabis Use, Cognition, and the Endocannabinoid System in HIV" — UCSD.

6. **NCT06808048** (Recruiting): "Medical Cannabis and Behavior" — University of Minnesota. Chronic pain patients using medical cannabis.

---

## Community Feedback Analysis

No community feedback submitted in Part A2 of the brief.

---

## Gaps & Flags

### 🚩 Data not verified from published primary sources:

1. **Dose ranges by preparation (FLAG — human review required):** No single published controlled dose-finding study provides canonical threshold/common/heavy dose values (in mg THC) for smoked cannabis flower in recreational/naive populations. The dose ranges synthesised in the effects section represent clinical trial doses (primarily for pain/therapeutic contexts), not the full recreational dose spectrum. The generation agent must not present these as confirmed published dose ranges without editorial verification.

2. **Tolerance timeline (FLAG — human review required):** The brief's tolerance data states "Half-life: 1.5 weeks; Full reset: 2.5 weeks." No published primary source was identified that confirms these specific timelines. CB1 receptor downregulation and recovery during abstinence are well-documented mechanistically, but precise human timelines vary and have not been confirmed from a single study.

3. **Seed data: No botanical family, genus, species in brief** — filled from POWO and McPartland 2018; no discrepancies found.

4. **Seed data: No withdrawal timeline** — filled from Connor et al. 2022 (PMID 34791767) and Bahji et al. 2020 meta-analysis (PMID 32271390).

5. **Cannabis concentrate dose data (FLAG):** No controlled clinical trial characterises specific dose-response for wax/dab/shatter preparations in humans. Community dose data not included per protocol.

6. **Diazepam interaction (FLAG):** The brief lists "Diazepam: caution." No specific clinical case report or quantitative PK/PD study was found characterising this cannabis-benzodiazepine interaction. The caution rating is plausible based on additive CNS depression mechanism, but lacks specific clinical case report evidence. Should be labelled as mechanism-based inference only.

7. **"Unknown" interactions in brief (e.g., LSD, 2C-x series, psychedelics, stimulants):** No published clinical PK data or case reports found for the vast majority of listed "unknown" interactions. These correctly remain "unknown." The generation agent should not infer severity ratings for these interactions.

8. **Nicotine interaction:** The brief flags "Nicotine: caution." Evidence supports synergistic respiratory risks (amplified lung cancer risk, combined tobacco/cannabis use [Ref 57]) but no PK-level cannabis-nicotine interaction data found. Caution rating is reasonable from public health standpoint; mechanism is primarily pharmacodynamic (co-administration of both substances via smoking route). Flag for human editor to assess whether the "caution" label is sufficient or needs mechanism note.

9. **Cannabis and alcohol interaction:** Not listed in the brief's interaction table, but well-documented: combined use substantially increases driving impairment and crash risk (greater than either alone). This should be considered for addition to the interaction table.

10. **CHS treatment papers:** Aprepitant case report for adolescent CHS (PMID 40965394) was found but not added to formal registry; recommend human editor review for inclusion.

11. **US federal rescheduling (FLAG — active change):** The rescheduling process is ongoing as of May 2026. The legal status section accurately reflects the most recent available information but should be flagged for timely editorial review.

12. **Legal status jurisdictions with low confidence:** 
    - Individual EU member state laws beyond Germany were not researched in detail (France, Spain, Netherlands, Italy). *FLAG: EU legal status beyond Germany should be researched by human editor.*
    - Specific penalty structures within Australian states not verified from primary regulatory sources.

13. **Fatalities:** No fatal human overdose from cannabis alone documented in literature. Cannabis is not associated with fatal respiratory depression (unlike opioids). The brief's seed data flags toxicity as "Inferred from pharmacological class — not sourced from literature. Review recommended." — This flag is appropriate and confirmed; the generation agent should note explicitly that no fatal human overdose from cannabis alone is documented.

14. **Drug testing detection windows:** Specific day-ranges for detection vary substantially and were synthesised from review sources rather than a single primary study. Flag for human review.

15. **THCA to THC conversion in actual cannabis preparations:** The 50-60% decarboxylation rate noted in Ref 34 applies to GC-MS without derivatization; thermal decarboxylation during actual smoking is expected to be near-complete but efficiency varies with temperature and method.